Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
Harvard Business School
Medtronic
Express Scripts

Last Updated: October 6, 2022

Details for Patent: 8,721,615


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,721,615 protect, and when does it expire?

Patent 8,721,615 protects FARXIGA and BYDUREON PEN and is included in two NDAs.

Protection for BYDUREON PEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seven patent family members in four countries.

Summary for Patent: 8,721,615
Title:Ampoule comprising an ampoule holder
Abstract: An ampoule including a casing, a facing side and a seal, wherein the casing has an outer diameter and the seal extends radially beyond the outer diameter and seals the facing side.
Inventor(s): Moser; Ulrich (Heimiswill, CH), Tschirren; Markus (Kirchberg, CH), Drunk; Annette (Bern, CH), Hirschel; Jurg (Aarau, CH), Kaenel; Celine (Zurich, CH), Mori; Kevin (Burgdorf, CH), Harris; Scott (San Diego, CA), Puddy; John (San Diego, CA), Chang; Victor (San Diego, CA)
Assignee: TecPharma Licensing AG (Burgdorf, CH)
Application Number:12/951,772
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,721,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-001 Jan 8, 2014 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Astrazeneca Ab FARXIGA dapagliflozin TABLET;ORAL 202293-002 Jan 8, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,721,615

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 025 011May 24, 2008

International Family Members for US Patent 8,721,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 102008025011 See Plans and Pricing
European Patent Office 2300079 See Plans and Pricing
European Patent Office 2300081 See Plans and Pricing
Taiwan 200948408 See Plans and Pricing
Taiwan I478746 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2009143641 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2009153132 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
McKinsey
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.